Articles tagged with: Revlimid

News»

[ by | Sep 6, 2013 5:48 pm | 13 Comments ]
Study Finds Revlimid-Dexamethasone Is Effective And Safe For Relapsed/Refractory Myeloma In ‘The Real World’

A recent Greek study looks at the efficacy and safety of Revlimid plus dexa­metha­sone for relapsed and refractory multiple myeloma patients in ‘the real world’ — that is, in patients being treated in standard clinical practice rather than clinical trials.

The study’s findings confirm that Revlimid (lenalidomide) plus dexa­metha­sone (Decadron) is effective and safe in day-to-day use among relapsed myeloma patients.

The majority of the patients in the study (77 percent) responded to treat­ment with Revlimid and dexa­metha­sone, with 20 percent achieving a complete response. According to the …

Read the full story »

News»

[ by and | Sep 4, 2013 9:21 pm | 2 Comments ]
Kyprolis Or Pomalyst For Dual-Refractory Myeloma - What Is The Survival Impact?

A new retrospective study provides insight into the benefit the new mye­lo­ma drugs Kyprolis and Pomalyst may provide to patients who are re­sis­tant to, or cannot tolerate, both Velcade and Revlimid.

The study’s results highlight how challenging it can be to find an effective treat­ment for patients who are “dual refractory” (resistant to both Velcade and Rev­li­mid).

Patients in the study who received either Kyprolis (carfilzomib) or Poma­lyst (poma­lido­mide, Imnovid) after becoming dual refractory had longer overall survival than those who were not treated with the new …

Read the full story »

News»

[ by | Aug 2, 2013 4:46 pm | 2 Comments ]
Revlimid Plus Dexamethasone Delays Progression And Extends Survival In High-Risk Smoldering Myeloma

Results from a Spanish Phase 3 study published late Wednesday in the New England Journal of Medicine indicate that treatment of high-risk smol­dering multiple myeloma with Revlimid plus dexamethasone delays pro­gression to symptomatic multiple myeloma and extends overall sur­viv­al.

In addition, the Revlimid (lenalidomide)-dexamethasone (Decadron) regi­men had an acceptable safety profile, according to the investigators.

Despite these findings – which would tend to support active treatment of high-risk smoldering myeloma – myeloma experts believe it is too early to begin treating all high-risk smoldering myeloma patients with anti-myeloma therapies. …

Read the full story »

News»

[ by | Jul 19, 2013 4:52 pm | Comments Off ]
Revlimid Leukemia Trial Halted – No Immediate Impact On Drug’s Use In Myeloma Expected

The U.S. pharmaceutical company Celgene (NASDAQ: CELG) reported yester­day the dis­continuation of the com­pany’s Phase 3 study of Revlimid for chronic lympho­cytic leu­kemia.

Preliminary results from the study, which compared treatment with Rev­li­mid (lenalidomide) to treatment with chlorambucil (Leukeran), showed more deaths among patients be­ing treated with Revlimid than those be­ing treated with chlor­ambucil.

The study, known as the “ORIGIN” trial, included 421 previously untreated chronic lymphocytic leukemia (CLL) pa­tients at least 65 years of age.

The U.S. Food and Drug Administration (FDA) also determined that the trial results …

Read the full story »

NewsFlash »

[ by | Jul 15, 2013 2:28 pm | One Comment ]

Revlimid Plus Dexamethasone Extends Progression-Free Survival In Newly Diagnosed Multiple Myeloma Patients – Results of a large international Phase 3 trial show that Revlimid (lenalidomide) plus dexamethasone (Decadron) ex­tends progression-free survival in newly diagnosed multiple myeloma patients who are not eligible for autologous stem cell transplantation, compared to treat­ment with melphalan (Alkeran), prednisone, and thalidomide (Thalomid). Based on these findings, Celgene, the manufacturer of Revlimid, will start the pro­cess of applying for approval of Revlimid as frontline treat­ment in the United States, Europe, and other countries. Although Celgene is widely used in the U.S. for the treatment of newly diagnosed myeloma patients, it is not officially approved for that use in the U.S. or any other country.  For more information, please see the related press release from Celgene.

Order Of Velcade And Revlimid Treatment May Not Matter In Treating Myeloma – Results from a recent retrospective study indicate that multiple myeloma patients benefit equally whether they are treated with Velcade (bortezomib) before Revlimid, or vice versa. However, patients with kidney disease tend to benefit from earlier use of Velcade-based therapies. Both Revlimid- and Velcade-based therapies have become common treatment options for myeloma patients. The investigators of this study were interested in de­ter­min­ing whether one drug should be given before the other. In their analysis, which was based on data for 208 myeloma patients treated between 2003 and 20089, the authors adjusted for a number of potential biases, such as patient age, number of previous therapies, and whether or not a patient had received a stem cell transplant.  The researchers found no significant difference in median overall survival between patients who received Revlimid first versus those who received Velcade first. For more information, please refer to the study in the journal Leukemia Research (abstract).

Unrelated Donor Stem Cell Transplant May Be An Under-Utilized Treatment Option For Myeloma – Find­ings from a retrospective study suggest that donor stem cell transplants using cells from unrelated donors may be underutilized for myeloma patients, particularly older myeloma patients. Specifically, the researchers found that only 11 percent of the myeloma patients they estimated to be eligible for an unrelated donor trans­plant actually underwent the procedure. Reasons for not undergoing a transplant included not being referred to a transplant center, worsening health condition of the patient, a prolonged search for a suitable donor, and financial issues. Donor (allogeneic) stem cell transplants involve infusing a patient with donor stem cells after high-dose chemotherapy. While the procedure has the potential to cure myeloma, it also is often accompanied by serious complications, including graft-versus-host-disease (GVHD), in which donor im­mune system cells recognize the patient’s cells as foreign and attack them. For more information, please re­fer to the study in the journal Biology of Blood and Marrow Transplantation (ab­stract).